Interaction of docetaxel ("Taxotere") with human P-glycoprotein

被引:76
作者
Shirakawa, K
Takara, K
Tanigawara, Y
Aoyama, N
Kasuga, M
Komada, F
Sakaeda, T
Okumura, K
机构
[1] Kobe Univ, Sch Med, Dept Hosp Pharm, Chuo Ku, Kobe, Hyogo 6500017, Japan
[2] Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan
[3] Keio Univ, Sch Med, Dept Hosp Pharm, Shinjuku Ku, Tokyo 1608582, Japan
来源
JAPANESE JOURNAL OF CANCER RESEARCH | 1999年 / 90卷 / 12期
关键词
docetaxel; Taxotere; P-glycoprotein; multidrug resistance; transport;
D O I
10.1111/j.1349-7006.1999.tb00723.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The interaction of docetaxel ("Taxotere") with P-glycoprotein (F-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. The basal-to-apical transport of [C-14]docetaxel in LLC-GA5-COL150 cells significantly exceeded that in LLC-PK1 cells, but the apical-to-basal transport was decreased in LLC-GA5-COL150 cells. The intracellular accumulation after its basal or apical application to LLC-GA5-COL150 cells was 4- to 20-fold lower than that of LLC-PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal-to-apical transport and increased the apical-to-basal transport of [C-14]docetaxel in LLC-GA5-COL150 cells, but verapamil affected only apical-to-basal transport. The intracellular accumulation after basal or apical application to LLC-GA5-CO150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp, The inhibition of [C-14]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine. was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. These observations indicate that it is necessary to consider the pharmacokinetic and pharmacodynamic interactions of docetaxel via P-gp.
引用
收藏
页码:1380 / 1386
页数:7
相关论文
共 33 条
[1]  
Aszalos A, 1998, ANTICANCER RES, V18, P2937
[2]   Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies [J].
Baggetto, LG .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 1997, 29 (04) :401-413
[3]   PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE [J].
BARTLETT, NL ;
LUM, BL ;
FISHER, GA ;
BROPHY, NA ;
EHSAN, MN ;
HALSEY, J ;
SIKIC, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :835-842
[4]  
BISSERY MC, 1991, CANCER RES, V51, P4845
[5]  
BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37
[6]   Clinical pharmacokinetics of docetaxel [J].
Clarke, SJ ;
Rivory, LP .
CLINICAL PHARMACOKINETICS, 1999, 36 (02) :99-114
[7]   DOCETAXEL [J].
CORTES, JE ;
PAZDUR, R .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2643-2655
[8]   Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death [J].
Dumontet, C ;
Sikic, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :1061-1070
[9]   THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE [J].
ENDICOTT, JA ;
LING, V .
ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 :137-171
[10]  
ERLICHMAN C, 1993, CANCER RES, V53, P4837